Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapyAuthor Response
作者： G. A. Spiridigliozzi , J. H. Heller , P. S. Kishnani , A. T. Van der Ploeg , B. J. Ebbink
DOI: 10.1212/WNL.0B013E31828B8AF0
关键词:
摘要: Editors’ Note: In their article “Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy,” Ebbink et al. reported data consistent Drs. Spiridigliozzi al.'s findings that CNS glycogen does not significantly impair cognitive function through the middle childhood years but may be related to delayed processing speed. Walters report results investigation into possible etiologies behind chocolate consumption lowering stroke risk. Megan Alcauskas, MD, and Robert C. Griggs, MD We would like inquire whether …
sci-hub.se 参考文章(3)
N. Weisglas-Kuperus, J. Jaeken, M. H. Lequin, W. F. M. Arts, A. T. van der Ploeg, B. J. Ebbink, F. K. Aarsen, C. M. van Gelder, J. M. P. van den Hout, Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy Neurology. ,vol. 78, pp. 1512- 1518 ,(2012) , 10.1212/WNL.0B013E3182553C11
Gail A. Spiridigliozzi, James H. Heller, Laura E. Case, Harrison N. Jones, Priya S. Kishnani, Early cognitive development in children with infantile Pompe disease. Molecular Genetics and Metabolism. ,vol. 105, pp. 428- 432 ,(2012) , 10.1016/J.YMGME.2011.10.012
Gail A. Spiridigliozzi, James H. Heller, Priya S. Kishnani, Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: Long-term follow-up†‡§ American Journal of Medical Genetics Part C-seminars in Medical Genetics. ,vol. 160, pp. 22- 29 ,(2012) , 10.1002/AJMG.C.31323